Hema K. Dave

Hematology | Oncology
1400 Forest Glen Rd Ste 335
Silver Spring, MD 20910

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

Treatment Selection for Non-muscle-invasive Bladder Cancer in an Emerging Treatment Era: A Patient Preference Study.

Treatment Selection for Non-muscle-invasive Bladder Cancer in an Emerging Treatment Era: A Patient Preference Study.

Journal: Urology
Published: October 07, 2025

Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphoma.

Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphoma.

Journal: Blood advances
Published: April 10, 2025

SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report.

SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report.

Journal: Journal for immunotherapy of cancer
Published: January 06, 2023

Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma.

Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma.

Journal: Blood advances
Published: November 10, 2022

Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma.

Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma.

Journal: The New England journal of medicine
Published: November 02, 2022

Robust immune responses to SARS-CoV-2 in a pediatric patient with B-Cell ALL receiving tisagenlecleucel.

Robust immune responses to SARS-CoV-2 in a pediatric patient with B-Cell ALL receiving tisagenlecleucel.

Journal: Pediatric hematology and oncology
Published: February 09, 2022

Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT.

Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT.

Journal: Blood advances
Published: December 15, 2021

Case Report: Fatal Complications of BK Virus-Hemorrhagic Cystitis and Severe Cytokine Release Syndrome Following BK Virus-Specific T-Cells.

Case Report: Fatal Complications of BK Virus-Hemorrhagic Cystitis and Severe Cytokine Release Syndrome Following BK Virus-Specific T-Cells.

Journal: Frontiers in immunology
Published: October 25, 2021

Intravenous anakinra for tisagenlecleucel-related toxicities in children and young adults.

Intravenous anakinra for tisagenlecleucel-related toxicities in children and young adults.

Journal: Pediatric hematology and oncology
Published: October 21, 2021

Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma.

Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma.

Journal: Blood advances
Published: May 21, 2021

Alignment of practices for data harmonization across multi-center cell therapy trials: a report from the Consortium for Pediatric Cellular Immunotherapy.

Alignment of practices for data harmonization across multi-center cell therapy trials: a report from the Consortium for Pediatric Cellular Immunotherapy.

Journal: Cytotherapy
Published: April 28, 2021

Novel TCR-like CAR-T cells targeting an HLA∗0201-restricted SSX2 epitope display strong activity against acute myeloid leukemia.

Novel TCR-like CAR-T cells targeting an HLA∗0201-restricted SSX2 epitope display strong activity against acute myeloid leukemia.

Journal: Molecular therapy. Methods & clinical development
Published: April 06, 2021
Showing 1-12 of 24

Last Updated: 09/26/2026